[1] [1] BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA: A Cancer Journal for Clinicians, 2024, 74(3): 229-263.

[4] [4] MEHTA N, KOTWANI P, NORMAN J, et al. AFP-L3 and DCP are superior to AFP in predicting waitlist dropout in HCC patients: results of a prospective study[J]. Liver Transplantation, 2023, 29(10): 1041-1049.

[5] [5] PANG B, LENG Y, WANG X, et al. A meta-analysis and of clinical values of 11 blood biomarkers, such as AFP, DCP, and GP73 for diagnosis of hepatocellular carcinoma[J]. Annals of Medicine, 2023, 55(1): 42-61.

[6] [6] HANIF H, ALI M J, SUSHEELA A T, et al. Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma[J]. World Journal of Gastroenterology, 2022, 28(2): 216-229.

[7] [7] MOHAMMED A F, XU C, CHENGBIN L I. Clinical utility of biomarkers of hepatocellular carcinoma[J]. Bratislava Medical Journal, 2024, 125(2): 102-106.

[8] [8] LI H, LIU H, YAN L J, et al. Performance of GALAD score and serum biomarkers for detecting NAFLD-related HCC: a systematic review and network meta-analysis[J]. Expert Review of Gastroenterology & Hepatology, 2023, 17(11): 1159-1167.

[9] [9] LI B, LIU A, WEN Y, et al. The prognostic values of serum markers in hepatocellular carcinoma after invasive therapies based on real‐world data[J]. Journal of Clinical Laboratory Analysis, 2021, 35(9): e23932.

[15] [15] FANG Y S, WU Q, ZHAO H C, et al. Do combined assays of serum AFP, AFP-L3, DCP, GP73, and DKK-1 efficiently improve the clinical values of biomarkers in decision-making for hepatocellular carcinoma? A meta-analysis[J]. Expert Review of Gastroenterology & Hepatology, 2021, 15(9): 1065-1076.

[18] [18] NORMAN J S, LI P J, KOTWANI P, et al. AFP-L3 and DCP strongly predict early hepatocellular carcinoma recurrence after liver transplantation[J]. Journal of Hepatology, 2023, 79(6): 1469-1477.

[19] [19] TAYOB N, KANWAL F, ALSARRAJ A, et al. The performance of AFP, AFP-3, DCP as biomarkers for detection of hepatocellular carcinoma (HCC): a phase 3 biomarker study in the United States[J]. Clinical Gastroenterology and Hepatology, 2023, 21(2): 415-423.

[20] [20] BURCIU C, ȘIRLI R, BENDE R, et al. A statistical approach to the diagnosis and prediction of HCC using CK19 and Glypican 3 biomarkers[J]. Diagnostics, 2023, 13(7): 1253.

[21] [21] HUAN L. Efficacy analysis of combined detection of 5 serological tumor markers including MIF and PIVKA-II for early diagnosis of primary hepatic cancer[J]. Pakistan Journal of Medical Sciences, 2021, 37(5): 1456-1460.

[22] [22] SCHOTTEN C, OSTERTAG B, SOWA J P, et al. GALAD score detects early-stage hepatocellular carcinoma in a european cohort of chronic hepatitis B and C patients[J]. Pharmaceuticals, 2021, 14(8): 735.

[24] [24] CHEN P, SONG H, XU W, et al. Validation of the GALAD model and establishment of a new model for HCC detection in Chinese patients[J]. Frontiers in Oncology, 2022, 12: 1037742.

[25] [25] PIRATVISUTH T, TANWANDEE T, THONGSAWAT S, et al. Multimarker panels for detection of early stage hepatocellular carcinoma: a prospective, multicenter, case-control study[J]. Hepatology Communications, 2022, 6(4): 679-691.

[31] [31] OLBRICH A, NIEMEYER J, SEIFFERT H, et al. The GALAD score and the BALAD-2 score correlate with transarterial and systemic treatment response and survival in patients with hepatocellular carcinoma[J]. Journal of Cancer Research and Clinical Oncology, 2024, 150(2): 81.

[32] [32] JITPRAPHAWAN O, RUAMTAWEE W, TREEWATCHAREEKORN M, et al. Diagnostic and prognostic performances of GALAD score in staging and 1-year mortality of hepatocellular carcinoma: a prospective study[J]. World Journal of Gastroenterology, 2024, 30(17): 2343-2353.

[40] [40] BANJAN B, VISHWAKARMA R, RAMAKRISHNAN K, et al. Targeting AFP-RAR complex formation: a potential strategy for treating AFP-positive hepatocellular carcinoma[J]. Molecular Diversity, 2024. https://doi.org/10.1007/s11030-024-10915-8.